Rigel Pharmaceuticals, Inc. (RIGL) Releases Preliminary Results for Q4 2025

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the Best Performing Affordable Stocks Under $40. On January 12, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its preliminary results for the fourth quarter of 2025 and also provided its 2026 outlook.

​Although the company is set to release its official results on March 3, the preliminary data suggests that the fourth quarter revenue will be around $69.8 million, compared to $57.6 million for the same period of 2024. Moreover, management expects fourth quarter 2025 gross product sales of $84.5 million, driven by TAVALISSE net product sales of $45.6 million, GAVRETO net product sales of $10.2 million, and REZLIDHIA net product sales of $9.6 million.

For the full year, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) expects to deliver around $294.3 million in revenue, up from $179.3 million in 2024. Looking ahead, management projects 2026 total revenue in the range of $275 million to $290 million.

​That said, Wall Street is bullish on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) after the release. On January 13, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock with a $57 price target.

​Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a clinical-stage biotechnology company that discovers and develops targeted, novel drugs in oncology, immunology, and immune oncology. Its product portfolio includes Tavalisse, Fostamatinib, and R835.

While we acknowledge the potential of RIGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.